- [4	00	2			
				÷	7	H

PART B - FEE(S) TRANSMITTA	\mathbf{AL}	
----------------------------	---------------	--

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 (703) 746-4000 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as a part correspondence address as formally all the patents of the patents of

papers. Each additional paper, such as an assignment or formal drawing have its own certificate of mailing or transmission. CUBIST PHARMACEUTICALS, INC. 65 HAYDEN AVENUE LIEXINGTON, MA 02421 Thereby certify that this Fcc(3) Transmittal is being deposited with the Smres Postal Service with sufficient postage for first class mail in an enaddressed to the Mail. Stop ISSUE FEB address above, or being factorism and the DSPTD (703) 746-4000, on the date indicated below. (Separation of the DSPTD (703) 746-4000, on the date indicated below.	CURRENT CORRESPONDENCE	ADDRESS (Note; Use Block) for	my change of address)		Note: A certificate o	f mailing can only be used f his certificate cannot be used	for domestic mailings of t
CURIST PHARMACEUTICALS, INC. TEX HAYDEN AVENUE TOTAL FEEL SO IT SHALL FROM THE AVENUE TEX HAYDEN AVENUE TOTAL FEEL SO IT SHALL FROM THE AVENUE					iii E_aL addition	crimings as no days ween lo	ant as famoul desiring we
### PRINCE OF INVENTION NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS APPLN. TYPE SMALL ENTITY ISSUE FEE FUBLICATION FEE TOTAL FEE(S) DUE ATTEM DUE NO STAND STAND AND ACTION OF THE AGENT STAND OF THE AGENT STAND ACTION OF THE AG			_		IN AC ITS OMIT CELETICI	c of maning of nansmasion,	
### PIBLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIGMATION NO. G9/738,742 12/15/2000 Jaton Hill CLIB—HS 2149 THE OF INVENTION: NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS CLIB—HS 2149 APPIN. TYPE SMALL ENTITY ISSUE FEE FUBLICATION FEE TOTAL FEE(5) DUE CARE DUE nonprovisional NO S1400 S300 S1400 S300 S1400 EXAMINER ART UNIT CLASS-SUBCLASS LUKTON, DAVID 1653 S14-900000 LUKTON, DAVID 1653 S14-900000 Change of correspondence address or indication of "Fee Address" (or Change of Correspondence address (or Change of Salida (Salida (C.	-1	Ce I hereby certify that I	rtificate of Mailing or Tran his Fcc(s) Transmittal is bein	smission ig deposited with the Unit
### PIBLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIGMATION NO. G9/738,742 12/15/2000 Jaton Hill CLIB—HS 2149 THE OF INVENTION: NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS CLIB—HS 2149 APPIN. TYPE SMALL ENTITY ISSUE FEE FUBLICATION FEE TOTAL FEE(5) DUE CARE DUE nonprovisional NO S1400 S300 S1400 S300 S1400 EXAMINER ART UNIT CLASS-SUBCLASS LUKTON, DAVID 1653 S14-900000 LUKTON, DAVID 1653 S14-900000 Change of correspondence address or indication of "Fee Address" (or Change of Correspondence address (or Change of Salida (Salida (CPI SER	Section Section	Smres Postal Service addressed to the Ma	with sufficient postage for fit il Stop ISSUE FEE address	rst class mail in an envelor s above, or being facsim
### PIBLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIGMATION NO. G9/738,742 12/15/2000 Jaton Hill CLIB—HS 2149 THE OF INVENTION: NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS CLIB—HS 2149 APPIN. TYPE SMALL ENTITY ISSUE FEE FUBLICATION FEE TOTAL FEE(5) DUE CARE DUE nonprovisional NO S1400 S300 S1400 S300 S1400 EXAMINER ART UNIT CLASS-SUBCLASS LUKTON, DAVID 1653 S14-900000 LUKTON, DAVID 1653 S14-900000 Change of correspondence address or indication of "Fee Address" (or Change of Correspondence address (or Change of Salida (Salida (. (g)		Kisa Gar	SME	Victor (1)	1 kg (703) 148-4000, on the	(Dopositor's nan
### PRESENCE OF CONTROL OF STATE OF PRINTED ON THE PATENT (Figure of year agents of a sasignee is identified below, the foodball production of this form is NOT a substantial for filing as assignee is identified below, the foodball production of this form is NOT a substantial for filing as assignee is identified below, the foodball production for (NAME OF ASSIGNEE NAME ADDRESSIONEE DATA TO BE PRINTED ON THE PATENT (Patent or year). **CUBIST PHARMACEUTICALS**, INC. Description for the propriete assignee category or categories (will not be printed on the patent). District of the propriete assignee category or categories (will not be printed on the patent). District of the Closines form agents of the propriete assignee category or categories (will not be printed on the patent). District of the Closines form agents of the patent of the patent. If an assignee is identified below, the foodball patent attempts of agents. If an assignee is identified below, the foodball patent pat	6 2005 CD		المترا كروه	LCRES	Vicincia	(2)	(Slamon
O9/738,742 12/15/2000 Jason Hill APPIN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(5) DUBY DORPOWISIONAL NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS APPIN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(5) DUBY DORPOWISIONAL NO SI 400 S300 S1 FEE PUBLICATION FEE TOTAL FEE(5) DUBY DIAGRAM ANT UNIT CLASS-SUBCLASS LILKTON, DAVID 1653 S14900000 Change of correspondence address or indication of "Fee Address" (37 FR. 1.363) S14900000 Change of correspondence address or indication for "Fee Address" indication fee Address indicated by "Fee Address" indicated the "Fee Address" indica					Rocilal	<i>-</i>	(Da
09/738,742 12/15/2000 Jaion Hill COSTUS 21/49 THE OF INVENTION: NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS APPLY, TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(5) DUE, CATE DUE nonprovisional NO S1400 S300 S1000000 EXAMPLE ART UNIT CLASS-SUBSCLASS LUKTON, DAVID 1653 S14-9000000 Change of correspondence address or indication of "Fee Address" [1653 S14-9000000 Change of correspondence address or indication of "Fee Address" [1653 S14-9000000 Change of correspondence address (or Change of Correspondence of Corresponden	ADDAY TON NO	ETI DIC DATE	FIRST	AMED INVEN	TOR		CONFIRMATION NO.
APPLY TYPE SMALL ENTITY ISSUE FEE FUBLICATION FEE TOTAL FREE(S) DUE, ROBINITY ISSUE FEE FUBLICATION FEE TOTAL FREE(S) DUE, ROBINITY ISSUE FEE FUBLICATION FEE TOTAL FREE(S) DUE, ROBINITY CLASS-SUBCLASS LUKTON, DAVID 1653 514-900000 Change of correspondence address or indication of "Foc Address" [17] Change of correspondence address (or Change of Correspondence address for Change of Correspondence address for Change of Correspondence address for TOTAL FREE(S) DUE, Change of correspondence address or indication for "Foc Address" [18] Change of correspondence address or indication of "Foc Address" [18] Change of correspondence address (or Change of Correspondence address for TOTAL FREE(S) DUE, Change of correspondence address or indication of "Foc Address" [18] 2. For printing on the patent from page, list CLASS-SUBCLASS 2. For printing on the patent from page, list CHANGE OF ADDRESS or CHANGE OF ADDRESS OF ADDR	ADEN		TIROT N		·		L
APPLY, TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FIELS, DUE, CATE DUE nonprevisional NO S1400 \$300 \$1 \$1000 \$100	·		ANTERNACIONAL ACT			10845	2147
Change of correspondence address or indication of "Fee Address" (37 FR 1,363). Change of correspondence address (or Change of Correspondence Address from PTO/S8/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/S8/122) attached. Use of a Customer PTO/S8/47; Rev 0,347, or more recent) attached. Use of a Customer Number is required. SSIGNEE NAME AND RESIDENCE DATA TO BE FRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the tocambent is NOT a substitute for filing and assignment. (A) NAME OF ASSIGNEE CUBIST PHARMACEUTICALS, INC. Lexington, MA SIlssee Fee Advance Order - # of Copies Publication Fee (No small entity discount permitted) Advance Order - # of Copies Publication Fee (No small entity discount permitted) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Publication Fee (No small entity discount permitted) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Date Change in Entity Status (from status indicated above) Date Director of the USFTO is presented to applicate in application identified above of the USFTO is presented to applicate in application identified above of the USFTO is presented to applicate in application identified above of the USFTO is presented to application identified above of the USFTO is presented to application in application is provided by the recent of the USFTO is presented to application in application in the application is not only the issue fee to the application identified above of the USFTO is presented to application in application in the application is a r	TLE OF INVENTION: NO	DAFT FILOSELLIDES V2	ANTIBACTERIAL AGE	N12			
Change of correspondence address or indication of "Fee Address" (37 Change of correspondence address for Indication of "Fee Address" (37 Change of correspondence address form PTO/SPI/22) attached. Use of a Customer PTO/SPI/22 attached. Use of a Customer PTO/SPI/22 attached. Use of a Customer PTO/SPI/22 attached. Use of a Customer PTO/SPI/27 attached use of a Customer PTO/SPI/27 attached. Use of a Customer PTO/SPI/27 attached	•					6	
Change of correspondence address or indication of "Fee Address" (37 R 1.503). Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Change in Entity Status (from starus indicated above) Change in Entity	ADDIN TYPE	SMALL ENTITY	ISSUE FEE	PU	BLICATION FEE	TOTAL FEE(S) DUE	PATE DUE
Change of correspondence address or indication of "Fee Address" (37 PR 1.503). Change of correspondence address or indication of "Fee Address" (37 Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Use of a Customer PTO/SN/47; key 0.40; or more recent) attached. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the tocambent has been fit recordation as set furth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing ad assignment. (A) NAME OF ASSIGNEE CUBIST PHARMACEUTICALS, INC. Lexington, MA SISSUE Fee CUBIST PHARMACEUTICALS, INC. Lexington, MA SI Issue Fee Publication Fee (6) are enclosed: Apyment of Fee(s) are enclosed: Apyment of Fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is utrached. Payment of Fee(s) is enclosed. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Discovered from strong from the patent in the pa						0000	14/42005
Change of correspondence address or indication of "Fee Address" (37 PR 1.503). Change of correspondence address or indication of "Fee Address" (37 Change of Correspondence Address from PTO/SN/122) attached. Change of correspondence address (or Change of Correspondence Address from PTO/SN/122) attached. Use of a Customer PTO/SN/47; key 0.40; or more recent) attached. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the tocambent has been fit recordation as set furth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing ad assignment. (A) NAME OF ASSIGNEE CUBIST PHARMACEUTICALS, INC. Lexington, MA SISSUE Fee CUBIST PHARMACEUTICALS, INC. Lexington, MA SI Issue Fee Publication Fee (6) are enclosed: Apyment of Fee(s) are enclosed: Apyment of Fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is utrached. Payment of Fee(s) is enclosed. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Advance Order - # of Copies Change in Entity Status (from status indicated above) Discovered from strong from the patent in the pa	nonprovisional	. 140					2
Change of correspondence address or indication of "Fee Address" (37 R 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent automove or agents OR, alternatively. 2. Change of correspondence address (or Change of Correspondence Address Theorem of the Correspondence Advance Order Account page, list (1) the names of up to 3 registered patent automovy or agents. If no name will appear on the patent of the patent of the Correspondence of	. EXAM	INER .	ART UNIT	ÇL	ASS-SUBCLASS		, °2, \ O
Change of correspondence address (or Change of Correspondence Address from PTO/SB/12) attached. Address from PTO/SB/12) attached. O'Fee Address' indication (or "Fee Address' Indication from PTO/SB/14; Rev 03-02 or more recent) attached. Use of a Customer Number is required. (2) the name of a single firm (having as a member a registered attentity or agent) and the names of up to 2 trajlatory or agent) and the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to a registered patent attorneys 3 trajlatory or agent of the patent of the names of up to a registered patent attorneys 3 trajlatory or agent of the patent of the names of up to a single firm (having as a member of up to 2 trajlatory or agent of the patent of the patent or agent of the patent of the form of t	LUKTON	, DAVID	1653		514-900000		05
Change of correspondence address (or Change of Correspondence Address from PTO/SB/12) attached. Address from PTO/SB/12) attached. O'Fee Address' indication (or "Fee Address' Indication from PTO/SB/14; Rev 03-02 or more recent) attached. Use of a Customer Number is required. (2) the name of a single firm (having as a member a registered attentity or agent) and the names of up to 2 trajlatory or agent) and the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to 2 trajlatory or agent of the patent of the names of up to a registered patent attorneys 3 trajlatory or agent of the patent of the names of up to a registered patent attorneys 3 trajlatory or agent of the patent of the names of up to a single firm (having as a member of up to 2 trajlatory or agent of the patent of the patent or agent of the patent of the form of t	Change of correspondence	address or indication of "Fo	c Address" (37 2, Fo	or printing on t	he pateut front page,	ist Timoth	V A Dours
Address form PTO/SP/122) attached. (2) the name of a single firm (having as a member a registrated attorney or agent) and the names of up to 2 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 2 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 3 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents. If no name is 1 registrated attorney or agents			Commenced (1) t	he names of u	p to 3 registered pate	nt attorneys I————	- 10/10
Tree Address' indication (or "Fee Address' Indication form PTO/SB47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee dam will appear on the patent. If an assignee is identified below, the location has been filling an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) JUL 1 4 2005 CUBIST PHARMACEUTICALS, INC. Lexington, MA case check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Governments for the following fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is attached. Payment by credit eard. Form PTO-2038 is attached. The following Instity Status (from status indicated above) A applicant claims SMALL ENTITY status, See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. c Director of the USPTO is proposited to apply the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered autorney or agent, or the assignee or other persons as shown by the records of the United States—attended Trudemark Office. Typed or printed name Timot by J. Douros Registration No. 41,716	Address form PTO/SB/12	2) attached.	(2)	he name of a s	ingle firm (having as	a member a 4	.N. Mandelbla
Number is required. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee dam will appear on the patent. If an assignee is identified below, the thousand has been filled an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) JUL 1 4 2005 CUBIST PHARMACFUTICALS, INC. Lexington, MA ease check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government by credit card. Form PTO-2038 is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby substituted by charge the required foc(s), or credit any overpaym Deposit Account Number Country (enclose an extra copy of this form). Advance Order - # of Copies Deposit Account Number Country (enclose an extra copy of this form). Change in Entity Status (from status indicated above) A applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). E Director of the USPTO is properted to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above person by the received of the United States Patent and Trademark Office. Authorized Signature Timothy J. Douros Registration No. 41,716	"Fee Address" indicati	ion (or "Fee Address" Indica	tion form regis	stered attorney	or agent) and the not attorneys or agents. I	nes of up to f no name is 2	
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been firecordation as set furth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) JUL 1 4 2005 CUBIST PHARMACEUTICALS, INC. Lexington, MA case check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Govern the following fee(s) are enclosed: 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Publication Fee (No small entity discount permitted) Advance Order - # of Copies Payment by credit eard. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpaym Deposit Account Number 100-1200 Change in Entity Status (from status indicated above) A applicant claims SMALL ENTITY status. See 37 CFR 1.27. De Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the applicant in dentified above the submitted on the patent of the USPTO is required will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other perest as shown by the records of the United Sance Fatent and Trudemark Office. Authorized Signature Timothy J. Douros Registration No. 41,716	Number is required.	t mote recent, amende es.	liste	d, no name wil	l be printed.	DE	CEIVED
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) CUBIST PHARMACEUTICALS, INC. Lexington, MA ease check the appropriate assignee category or categories (will not be printed on the patent): Individual	ASSIGNEE NAME AND	RESIDENCE DATA TO B	E PRINTED ON THE PA	TENT (print o	r typc)		IDE/IAD
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) JUL 14 ZUUS CUBIST PHARMACFUTICALS, INC. Lexington, MA ease check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Govern the following fee(s) are enclosed: Ab. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is attached. Payment by credit eard. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpaym Deposit Account Number (enclose an extra copy of this form). Change in Entity Status (from status indicated above) Sa. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. In Director of the USPTO is papiested to apply the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignce or other process as shown by the recent of the United States Fateur and Trademark Office. Typed or printed name Timothy J. Douros Registration No. 41,716	PLEASE NOTE: Unless recordation as set furth in	an assignee is identified be 37 CFR 3.11. Completion	low, no assignee data wi	ll appear on the	ne patent. If an assig an assignment,	nee is identified below, the	document has been filed
CUBIST PHARMACEUTICALS, INC. Lexington, MA ease check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Govern. The following fee(s) are enclosed: Ab. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is attached. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above OTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignee or other prevents as shown by the records of the United States Fatent and Trudemark Office. Authorized Signature Typed or printed name Timothy J. Douros Registration No. 41,716							1 4 2005
ease check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Govern. The following fec(s) are enclosed: Ab. Payment of Fec(s):	(W) INTIME OF MODICIAL	.	(2),442,.	J., 104. (C.)			
Typed or printed name 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is attached. Payment by credit eard. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpaym beposit Account Number. The Director is hereby authorized by charge the required fee(s), or credit any overpaym beposit Account Number. The Director of the USPTO is required to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above of the USPTO is required will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignee or other prevents as shown by the recepts of the United States Fatent and Trudemark Office. Typed or printed name Timothay J. Douros Authorized Signature Timothay J. Douros Registration No. 41,716							
Typed or printed name 4b. Payment of Fee(s): 4b. Payment of Fee(s): 4b. Payment of Fee(s): A check in the amount of the fee(s) is enclosed. Payment by credit eard. Form PTO-2038 is attached. Payment by credit eard. Form PTO-2038 is attached. Payment by credit eard. Form PTO-2038 is attached. Payment by charge the required fee(s), or credit any overpaym Deposit Account Number Deposit Account Number (enclose an extra copy of this form). Change in Entity Status (from status indicated above) B a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is required to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above of the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignce or other perest as shown by the records of the United States Extent and Trudemark Office. Authorized Signature Timothy J. Douros Registration No. 41,716	CUBIST PHAI	RMACEUTICALS, 1	NC. Lex	ington,	MA		
Advance Order - # of Copies Payment by credit card. Form PTO-2038 is antached. The Director is hereby authorized by charge the required fcc(s), or credit any overpaym Deposit Account Number (enclose an extra copy of this form). Change in Entity Status (from status indicated above) Ba. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is required to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue foe to the application identified above or control of the Uspto of the United States Fatent and Trudemark Office. Authorized Signature Timothy J. Douros Registration No. 41,716	. / / / /	•		-		Corporation or other private or	mun éntity 🚨 Governme
Publication Fcc (No small entity discount permitted) Advance Order - # of Copies Advance Order - # of Copies The Director is hereby authorized by charge the required fcc(s), or credit any overpaym peposit Account Number Change in Entity Status (from status indicated above) Ba. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is required to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue for to the application identified above of the Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignce or other prevents as shown by the recogn of the United States Fatent and Trudemark Office. Timothy J. Douros Registration No. 41,716	ease check the appropriate	assignee category or catego	ries (will not be printed on	the patent) :		Corporation or other private gr	roup entity 🚨 Governme
Advance Order - # of Copies	ease check the appropriate. The following fec(s) are o	assignee category or catego	ries (will not be printed on 4b, Payme	the patent) :	Individual 🖾 (•	roup entity Governme
Change in Entity Status (from status indicated above) 23 a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. 35 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 36 a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. 36 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 37 a. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 38 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 39 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 31 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 32 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 33 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 34 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 35 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 36 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 37 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 38 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 39 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 30 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 31 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 31 c. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). 31 c. Applicant is no longer claiming SMA	ease check the appropriate The following fee(s) are o	assignee category or catego	ries (will not be printed on 4b. Payme	the patent): ent of Fee(s): sheek in the arr	Individual 🔯 (nclosed	roup entity Governme
Authorized Signature Timothy J. Douros D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). D. Applican	ease check the appropriate The following fee(s) are one of the last of the la	assignee category or category	ries (will not be printed or 4b. Payme A c D A c	the patent): ent of Fec(s): check in the any	ount of the fee(s) is e card. Form PTO-203	nelosed. 8 is attached.	
TimoLay J. Douros Director of the USPTO is required to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above OTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignce or other prevent as shown by the recogn of the United States Fatent and Trudemark Office. Date Option 1, 2005 TimoLay J. Douros Registration No. 41,716	ease check the appropriate The following fee(s) are one of the following fee(s) are one of the following fee(s) are of the fee(assignee category of categor enclosed: mall entity discount permitte Copies	de (will not be printed or 4b, Payme a do	the patent): ent of Fec(s): check in the any	ount of the fee(s) is e card. Form PTO-203	nelosed. 8 is attached.	
Authorized Signature	ease check the appropriate The following fee(s) are of the fee(s) are of the following fee(s) are of the fee(s) are o	assignee category or category	d) Payment of the printed or the printed or the payment of the pay	on the patent): cut of Fec(s): check in the any ment by creding Director is he it Account Nur	nount of the fec(s) is estart. Form PTO-203	nclosed. 8 is anached. charge the required fec(s), or(enclose an extra or	r credit any overpayment copy of this form).
Typed or printed name Timothy J. Douros Registration No. 41,716	ease check the appropriate The following fee(s) are on the same of the same o	assignee category of category	db. Paymed and a db. Pa	the patent): cut of Fec(s): check in the anyment by credit c Director is he account Nur	Individual (a) count of the fec(s) is estend Form PTO-203 ereby authorized by other 50-13869	nclosed. 8 is attached. charge the required fcc(s), or (enclose an extra of	r credit any overpayment copy of this form). CFR 1.27(g)(2).
is called in a find a sting is manyised by 27 CVD 1211. The information is manyised to obtain as rotain a honofit by the multiple which is to file fand by the IEDTO to re-	ease check the appropriate The following fee(s) are of the last o	assignee category of category	db. Paymed and a db. Pa	the patent): cut of Fec(s): check in the anyment by credit c Director is he account Nur	Individual (a) count of the fec(s) is estend Form PTO-203 ereby authorized by other 50-13869	nelosed. 8 is attached. charge the required fec(s), or	r credit any overpayment copy of this form). CFR 1.27(g)(2), ation identified above, the assignce or other part
his collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering preparir ibmitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to collisions for reducing this burden, should be sent to the Chief Information Officer, U.S. Parent and Trademark Office, U.S. Department of Commerce	ease check the appropriate The following fee(s) are of the large fee All Issue Fee Advance Order - # of Change in Entity Status (comparing fee) A Applicant claims Shape Director of the USPTO in OTE: The Issue Fee and Puterest as shown by the recognition.	assignee category of category	db. Payme 4b. Payme 4b. Payme A c d) Pay Th. Deposi 7 CFR 1.27. Db. A te Fee and Publication Fee will not be accepted from a ant and Trudemark Office.	the patent): cut of Fec(s): check in the anyment by credit c Director is he account Nur	Individual is count of the fee(s) is exact. Form PTO-203 ereby anthorized by other longer claiming SMA re-apply any previous an the applicant; a report of the property of the	nelosed. 8 is attached. charge the required fec(s), or (enclose an extra of the leading of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid issue fee to the application of the special paid is special paid is special paid in the special paid in the special paid is special paid in the speci	r credit any overpayment copy of this form). CFR 1.27(g)(2), ation identified above, the assignee or other part

Box 1450, Alexandra, Virginia 22313-1450. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandra, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

07/15/2005 HDEMESS2 00000018 501986 09738742


PTOL-85 (Rev. 12/04) Approved for use through 04/30/2007.

FC:1501 02 FC:1504

1400.00 DA 300.00 DA OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE









Deposit Account Branch To:

Viana Daly From:

Intellectual Property Administrator

Tel: 781 860 8660

Fax: 781 860 1407

	•				
Fax:	703 3	08 6778	Pages	: 2 (including co	ver sheet)
P ho ne:	!		Date:	May 25, 2005	
Re:	Depos	sit Account 50-1986	CC:		
Un	gent	⊠ For Review	☐ Please Comment	Please Reply	Please Recycle
		·-			

Comments:

Our April 2005 statement shows a debit for payment of a large entity issue fee for US Serial No. 09/738,742. However, Cubist Pharmaceuticals, Inc. has requested a change in entity status as shown on the attached Fee(s) Transmittal and thus qualifies for the reduced issue fee as a small entity.

We respectfully ask that you credit the sum of \$700 to our deposit account, which is the difference between the small and large entity issue fees.

Thank you for your attention to this matter. Please contact me if you have any questions.

THIS FAX IS FOR THE SOLE USE OF THE INTENDED RECIPIENT(S) AND CONTAINS CONFIDENTIAL AND PRIVILEGED INFORMATION. ITS CONTENTS SHOULD NOT BE DISCLOSED NOR SHOULD IT BE GIVEN OR COPIED TO ANYONE. IF YOU ARE NOT THE INTENDED RECIPIENT, PLEASE CONTACT THE SENDER AND DESTROY ALL COPIES OF THE ORIGINAL MESSAGE. THANK YOU.

USPTO Dep AcctFAX(refundreq) 052505

65 Hayden Avenue, Lexington, MA 02421

P. 781.860.8660

F. 781.860.1407

www.cubist.com